Literature DB >> 22644033

High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.

José M Miró1, José M Entenza, Ana Del Río, Maria Velasco, Ximena Castañeda, Cristina Garcia de la Mària, Marlyse Giddey, Yolanda Armero, Juan M Pericàs, Carlos Cervera, Carlos A Mestres, Manuel Almela, Carlos Falces, Francesc Marco, Philippe Moreillon, Asuncion Moreno.   

Abstract

We describe 3 patients with left-sided staphylococcal endocarditis (1 with methicillin-susceptible Staphylococcus aureus [MSSA] prosthetic aortic valve endocarditis and 2 with methicillin-resistant S. aureus [MRSA] native-valve endocarditis) who were successfully treated with high-dose intravenous daptomycin (10 mg/kg/day) plus fosfomycin (2 g every 6 h) for 6 weeks. This combination was tested in vitro against 7 MSSA, 5 MRSA, and 2 intermediately glycopeptide-resistant S. aureus isolates and proved to be synergistic against 11 (79%) strains and bactericidal against 8 (57%) strains. This combination deserves further clinical study.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22644033      PMCID： PMC3421550          DOI： 10.1128/AAC.06449-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

2.  Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding.

Authors:  Abhay Dhand; Arnold S Bayer; Joseph Pogliano; Soo-Jin Yang; Michael Bolaris; Victor Nizet; Guiquing Wang; George Sakoulas
Journal:  Clin Infect Dis       Date:  2011-07-15       Impact factor: 9.079

3.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

4.  Phosphonomycin, a new antibiotic produced by strains of streptomyces.

Authors:  D Hendlin; E O Stapley; M Jackson; H Wallick; A K Miller; F J Wolf; T W Miller; L Chaiet; F M Kahan; E L Foltz; H B Woodruff; J M Mata; S Hernandez; S Mochales
Journal:  Science       Date:  1969-10-03       Impact factor: 47.728

5.  In vitro activity of LY146032 alone and in combination with other antibiotics against gram-positive bacteria.

Authors:  E Debbia; A Pesce; G C Schito
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

6.  Staphylococcus aureus endocarditis: a consequence of medical progress.

Authors:  Vance G Fowler; Jose M Miro; Bruno Hoen; Christopher H Cabell; Elias Abrutyn; Ethan Rubinstein; G Ralph Corey; Denis Spelman; Suzanne F Bradley; Bruno Barsic; Paul A Pappas; Kevin J Anstrom; Dannah Wray; Claudio Q Fortes; Ignasi Anguera; Eugene Athan; Philip Jones; Jan T M van der Meer; Tom S J Elliott; Donald P Levine; Arnold S Bayer
Journal:  JAMA       Date:  2005-06-22       Impact factor: 56.272

7.  Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database.

Authors:  José M Miro; Ignasi Anguera; Christopher H Cabell; Anita Y Chen; Judith A Stafford; G Ralph Corey; Lars Olaison; Susannah Eykyn; Bruno Hoen; Elias Abrutyn; Didier Raoult; Arnold Bayer; Vance G Fowler
Journal:  Clin Infect Dis       Date:  2005-07-06       Impact factor: 9.079

8.  Cefotaxime in combination with other antibiotics for the treatment of severe methicillin-resistant staphylococcal infections.

Authors:  H Portier; A Kazmierczak; F Lucht; J C Tremeaux; P Chavanet; J M Duez
Journal:  Infection       Date:  1985       Impact factor: 3.553

Review 9.  Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections.

Authors:  Nikos Roussos; Drosos E Karageorgopoulos; George Samonis; Matthew E Falagas
Journal:  Int J Antimicrob Agents       Date:  2009-10-13       Impact factor: 5.283

10.  Induction kinetics of the Staphylococcus aureus cell wall stress stimulon in response to different cell wall active antibiotics.

Authors:  Vanina Dengler; Patricia Stutzmann Meier; Ronald Heusser; Brigitte Berger-Bächi; Nadine McCallum
Journal:  BMC Microbiol       Date:  2011-01-20       Impact factor: 3.605
View more
  31 in total

1.  Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.

Authors:  Ashley D Hall Snyder; Brian J Werth; Poochit Nonejuie; John P McRoberts; Joe Pogliano; George Sakoulas; Juwon Yim; Nivedita Singh; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

2.  Characterization of a novel two-component regulatory system, HptRS, the regulator for the hexose phosphate transport system in Staphylococcus aureus.

Authors:  Joo Youn Park; Jong Wan Kim; Bo Youn Moon; Juyeun Lee; Ye Ji Fortin; Frank W Austin; Soo-Jin Yang; Keun Seok Seo
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

Review 3.  Fosfomycin: Resurgence of an old companion.

Authors:  Sangeeta Sastry; Yohei Doi
Journal:  J Infect Chemother       Date:  2016-02-28       Impact factor: 2.211

4.  Daptomycin plus fosfomycin, a synergistic combination in experimental implant-associated osteomyelitis due to methicillin-resistant Staphylococcus aureus in rats.

Authors:  Tilman Lingscheid; Wolfgang Poeppl; Dominik Bernitzky; Luzia Veletzky; Manuel Kussmann; Roberto Plasenzotti; Heinz Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

5.  Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model.

Authors:  Stéphane Corvec; Ulrika Furustrand Tafin; Bertrand Betrisey; Olivier Borens; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

6.  Daptomycin In Vitro Activity against Methicillin-Resistant Staphylococcus aureus Is Enhanced by d-Cycloserine in a Mechanism Associated with a Decrease in Cell Surface Charge.

Authors:  O Gasch; S K Pillai; J Dakos; S Miyakis; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

Review 7.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

8.  High activity of Fosfomycin and Rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model.

Authors:  Raluca Mihailescu; Ulrika Furustrand Tafin; Stéphane Corvec; Alessandra Oliva; Bertrand Betrisey; Oliver Borens; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

Review 9.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

10.  Efficacy of fosfomycin compared to vancomycin in treatment of implant-associated chronic methicillin-resistant Staphylococcus aureus osteomyelitis in rats.

Authors:  Wolfgang Poeppl; Tilman Lingscheid; Dominik Bernitzky; Uwe Y Schwarze; Oliver Donath; Thomas Perkmann; Nicolas Kozakowski; Roberto Plasenzotti; Gottfried Reznicek; Heinz Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.